IND PROCEDURES | US FDA

September 8, 2022

Have a look at this infographic that Extedo® and Asphalion have prepared with the summary updates in terms of publishing and eSubmission at a regional level, focused on INDs for US FDA!

The US law requires that a drug be the subject of an approved marketing application before it is transported across state lines, e.g., to clinical investigators. The IND is the way for the sponsor to get this exemption from the FDA. So, before a new drug in a preclinical development status can be used for clinical studies, an IND has to be submitted.

ASPHALION and our partner Extedo® can offer you a wide range in Regulatory Services and Solutions in the United States. Asphalion can support you throughout the whole lifecycle of the IND procedure in a variety of activities.

Check the document here:

Flyer IND Publishing Asphalion Extedo

Search News & Events

  • Filter by category

Share

Related news and events

RBDCOV | 14-months follow-up meeting

The second face-to-face RBDCOV meeting is taking place today at Palau Macaya in Barcelona! Our expert, Chris Mann, is attending the meeting in person. After

2nd eAF (DADI) Newsletter has been published on the EMA website!

2nd eAF (DADI) Newsletter has been published on the EMA website: The web-based Human Variations electronic application form (eAF) for Centrally Authorised Products (CAPs) – often referred to by its former project name, DADI – has been available for use as of 4 November 2022 on the new Product Lifecycle Management (PLM) Portal.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting